Likewise, the LEADER trial concluded that a related GLP‐1 mimetic, namely, liraglutide, was beneficial in reducing the rate of non‐fatal myocardial infarction, stroke and first occurrence of death from cardiovascular causes (Marso, Daniels, et al., 2016). The gene discussed is GCG; the disease is myocardial infarction.